GLP-1 Drugs Cut PMOS Weight by 42 Pounds, Show Early Hormone Gains
Updated
Updated · The Associated Press · Aug 15
GLP-1 Drugs Cut PMOS Weight by 42 Pounds, Show Early Hormone Gains
3 articles · Updated · The Associated Press · Aug 15
Summary
Early PMOS trial data showed 8 of 11 women who finished semaglutide treatment lost at least 10% of body weight, with median loss of about 42 pounds and testosterone down 52%.
Those gains matter because PMOS affects 1 in 8 women worldwide and is driven in part by insulin resistance, which can raise testosterone and trigger irregular periods, acne and excess facial hair.
In the Colorado study, 18-year-old Charlotte Touzalin took weekly semaglutide shots for 10 months and saw slower hair growth, normalized periods and less constant hunger.
Three studies led by Dr. Melanie Cree found women on GLP-1 drugs lost more weight than control groups, while blood sugar, insulin and testosterone also fell, though researchers say larger trials are still needed.
Insurance remains a major obstacle because GLP-1s are not approved for PMOS; Touzalin lost free access after her study ended in June and her family is now fighting for coverage.